GO:0002885 positive regulation of hypersensitivity: Immune Amplification Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002885 (positive regulation of hypersensitivity) describes any biological process that activates or increases the frequency, rate, or extent of hypersensitivity, the exaggerated immune response to otherwise harmless antigens.
• The term is a biological_process node that sits downstream of antigen recognition and upstream of clinical symptoms such as wheezing, urticaria, and anaphylaxis.
• Key molecular drivers include IgE and its high-affinity receptor, epithelial alarmins such as IL-25/IL-33/TSLP, Th2 cytokines (IL-4, IL-5, IL-13), and IL-17A.
• Positive regulation can be initiated by allergen challenge in sensitized individuals, which is the basis of standardized nasal allergen challenge models used in clinical research.
• Dysregulated positive regulation of hypersensitivity underlies allergic rhinitis, chronic spontaneous urticaria, food allergy, and allergic asthma.
• CRISPR knockout, knock-in, and overexpression models are essential to test whether a candidate gene causally amplifies or dampens hypersensitivity responses.
Description
GO:0002885, positive regulation of hypersensitivity, is a Gene Ontology biological_process term that captures any process which activates or increases the frequency, rate, or extent of hypersensitivity. Hypersensitivity is the exaggerated and often harmful immune reaction to antigens that are otherwise innocuous, and its positive regulation is therefore a central node in allergy research. Understanding this term helps researchers connect molecular triggers, such as allergen exposure and IgE cross-linking, to the cellular and tissue events that produce clinical allergic disease. The term is deliberately broad: it encompasses signals from epithelial cells, innate immune cells, B cells, and T cells that collectively lower the threshold for, or amplify the magnitude of, a hypersensitivity response. Because positive regulation of hypersensitivity is mechanistically upstream of symptoms, it is a high-value target for both mechanistic studies and therapeutic development. Standardized provocation models, such as nasal allergen challenge, have been developed to quantify how strongly a given stimulus drives this process in humans. In parallel, CRISPR-based cell models allow researchers to interrogate individual genes for causal roles in amplifying hypersensitivity.
positive regulation of hypersensitivity At A Glance
| GO ID | GO:0002885 |
|---|---|
| GO term | positive regulation of hypersensitivity |
| Ontology | biological_process |
| Synonym | activation of hypersensitivity; stimulation of hypersensitivity; up regulation of hypersensitivity; up-regulation of hypersensitivity; upregulation of hypersensitivity |
| Major function | Activates or increases the frequency, rate, or extent of hypersensitivity |
| Biological context | Allergic inflammation, immediate and delayed hypersensitivity, Th2 and Th17 responses |
| Representative triggers | Allergen exposure, IgE cross-linking, epithelial alarmins, cytokines |
| Representative readouts | Wheal-and-flare, nasal symptom scores, mediator release, cytokine production |
| Therapeutic relevance | Targets include IgE, IL-4Ralpha, JAK1, plasma kallikrein, and SIRT6-linked pathways |
What Is GO:0002885?
In our own words, positive regulation of hypersensitivity (GO:0002885) refers to any biological process that activates, stimulates, or upregulates hypersensitivity, thereby increasing how often, how fast, or how strongly a hypersensitivity reaction occurs. It is not hypersensitivity itself, but the regulatory layer that pushes the response upward. This includes signals that enhance sensitization to allergens, promote effector-cell activation, or amplify inflammatory mediator release during a hypersensitivity reaction.
Why Is positive regulation of hypersensitivity Important in Cell Biology?
Positive regulation of hypersensitivity is important because it defines the mechanistic step at which a harmless antigen becomes a clinically significant allergic reaction. If this regulatory process is overactive, patients experience more frequent or more severe episodes of allergic rhinitis, urticaria, asthma, or food allergy. If it can be selectively dampened, symptoms may be controlled without broadly suppressing protective immunity. Therefore, mapping the genes and signals that positively regulate hypersensitivity is directly relevant to biomarker discovery, drug target validation, and the design of safer immunomodulatory therapies.
• It is the mechanistic bridge between allergen recognition and clinical allergic symptoms.
• It governs the intensity of immediate hypersensitivity reactions such as urticaria and anaphylaxis.
• It is central to chronic spontaneous urticaria, where unmet clinical needs remain high.
• It contributes to allergic rhinitis through epithelial and immune cell crosstalk.
• It is implicated in food allergy, where Tert-IL10 signaling can modulate reactivity.
• It involves IL-17A pathogenicity in allergic airway inflammation and remodeling.
• It is a target space for approved and emerging drugs such as abrocitinib and sebetralstat.
• It can be quantified experimentally using standardized allergen challenge protocols.
• It provides a framework for CRISPR screens that identify amplifiers of allergic inflammation.
• It helps distinguish sensitization from effector-phase amplification in allergy research.
What Happens During positive regulation of hypersensitivity?
Allergen recognition and sensitization
In simple terms: The immune system first learns to see a harmless substance as a threat.
Positive regulation of hypersensitivity begins when an allergen is encountered and processed by antigen-presenting cells, leading to sensitization. Standardized nasal allergen challenges in sensitized individuals demonstrate that controlled allergen exposure can reproducibly trigger hypersensitivity responses, confirming that recognition of the allergen is the initiating step. IgE produced during sensitization binds to high-affinity receptors on mast cells and basophils, poising them for activation.
IgE-dependent effector cell activation
In simple terms: Allergen-specific IgE acts like a trigger on the surface of immune cells.
Once IgE is bound to effector cells, re-exposure to allergen cross-links IgE and activates mast cells and basophils. IgE is now recognized not only as a trigger of immediate hypersensitivity but also as a regulator of adaptive immune responses, which can further amplify the hypersensitivity cascade. This step is a major positive regulatory node because it converts a small allergen dose into a large mediator release.
Epithelial alarmin and cytokine amplification
In simple terms: Barrier cells release alarm signals that call in more immune cells.
Epithelial cells release alarmins and cytokines that recruit and activate Th2 and Th17 cells. Epithelial SIRT6 has been shown to govern IL-17A pathogenicity and to drive allergic airway inflammation and remodeling, illustrating how an epithelial regulator can positively regulate hypersensitivity. LRRC8A drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis, providing another example of a molecular amplifier of the hypersensitivity response.
Th2/Th17 cytokine feedback
In simple terms: Cytokines keep the allergic reaction going and make it stronger.
IL-4, IL-5, IL-13, and IL-17A act in feedback loops that sustain and intensify allergic inflammation. IL-17A pathogenicity in the airway is linked to epithelial SIRT6, and this axis promotes remodeling as well as inflammation. These cytokine loops are a key reason why positive regulation of hypersensitivity can become chronic rather than self-limited.
Mediator release and clinical expression
In simple terms: The amplified signals finally produce symptoms like wheals, sneezing, or wheezing.
Histamine, leukotrienes, and other mediators released by activated effector cells produce the clinical features of hypersensitivity, including urticaria, nasal congestion, and bronchoconstriction. In chronic spontaneous urticaria, these mediator-driven events are persistent and represent an unmet clinical need, underscoring the importance of the positive regulatory steps that sustain them. Therapeutic blockade of IgE, IL-4Ralpha, JAK1, or plasma kallikrein can interrupt these steps and reduce symptoms.
Key Genes Involved in GO:0002885 positive regulation of hypersensitivity
The following genes and proteins have been experimentally linked to processes that positively regulate hypersensitivity, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGHE | Encodes IgE heavy chain constant region; IgE binds mast cells and basophils | Central to immediate hypersensitivity and adaptive immune regulation |
| FCER1A | High-affinity IgE receptor alpha chain on effector cells | Mediates IgE cross-linking and mast cell activation |
| IL4 | Th2 cytokine driving IgE class switching and Th2 polarization | Amplifies allergic inflammation |
| IL5 | Eosinophil growth and survival factor | Sustains eosinophilic inflammation in hypersensitivity |
| IL13 | Th2 cytokine promoting mucus production and airway hyperreactivity | Key amplifier of allergic airway disease |
| IL17A | Th17 cytokine linked to neutrophilic inflammation and remodeling | Pathogenicity governed by epithelial SIRT6 |
| SIRT6 | Epithelial deacetylase regulating IL-17A pathogenicity | Drives allergic airway inflammation and remodeling |
| LRRC8A | Volume-regulated anion channel component | Drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis |
| TERT | Telomerase reverse transcriptase; linked to Tert-IL10 signaling | Tert methylation regulation alleviates food allergy |
| IL10 | Anti-inflammatory cytokine downstream of Tert signaling | Modulates food allergy severity |
| JAK1 | Janus kinase transducing cytokine signals | Target of abrocitinib in inflammatory allergic disease |
| IL4R | IL-4 receptor alpha chain | Shared receptor for IL-4 and IL-13 signaling |
| KLKB1 | Plasma kallikrein involved in bradykinin generation | Target of sebetralstat for hereditary angioedema attacks |
| TSLP | Epithelial alarmin promoting Th2 responses | Amplifies hypersensitivity initiation |
| IL33 | Epithelial alarmin activating innate lymphoid cells | Promotes Th2-type hypersensitivity |
| IL25 | Epithelial cytokine driving Th2 responses | Contributes to allergic inflammation |
| MS4A2 | Beta chain of the high-affinity IgE receptor | Amplifies mast cell signaling |
How Is positive regulation of hypersensitivity Regulated?
Positive regulation of hypersensitivity is itself regulated at multiple levels. Epithelial SIRT6 controls the pathogenicity of IL-17A and thereby modulates allergic airway inflammation and remodeling, showing that epigenetic regulators can set the gain on hypersensitivity. LRRC8A influences NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis, linking ion channel activity to amplification of the response. Tert methylation regulates the Tert-IL10 signaling pathway and can alleviate food allergy, indicating that DNA methylation and telomerase-related signaling participate in negative or positive tuning of hypersensitivity. Cytokine signaling through JAK1 and IL-4Ralpha provides additional checkpoints that can be pharmacologically modulated, as illustrated by abrocitinib. Finally, the plasma kallikrein pathway targeted by sebetralstat shows that protease cascades can regulate the intensity of hypersensitivity-related edema attacks.
positive regulation of hypersensitivity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LRRC8A | Allergic rhinitis | Knockout airway epithelial cells and allergen-challenged mouse models |
| SIRT6 | Allergic airway inflammation and remodeling | Epithelial-specific knockout and overexpression models |
| TERT | Food allergy | Tert methylation-edited or knock-in models with IL10 readouts |
| IL17A | Neutrophilic allergic airway disease | Knockout and reporter knock-in mice |
| IGHE / FCER1A | Immediate hypersensitivity and urticaria | Humanized IgE receptor knock-in models |
Allergic rhinitis
Allergic rhinitis is a common hypersensitivity disease in which allergen exposure triggers nasal inflammation. LRRC8A has been shown to drive NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis, identifying a molecular amplifier of the hypersensitivity response. Standardized nasal allergen challenge is used to quantify the responsiveness of the nasal mucosa in sensitized individuals, making it a direct human model of positive regulation of hypersensitivity.
Chronic spontaneous urticaria
Chronic spontaneous urticaria is characterized by recurrent wheals and/or angioedema without an obvious external trigger. A GA2LEN task force report highlighted unmet clinical needs in this condition, reflecting the difficulty of controlling the positive regulatory processes that sustain mast cell and basophil activation. Therapies that target IgE or downstream kinases aim to reduce this amplification.
Food allergy
Food allergy involves exaggerated immune responses to dietary antigens. Regulation of Tert methylation alleviates food allergy via the Tert-IL10 signaling pathway, demonstrating that epigenetic and cytokine signals can modulate the intensity of hypersensitivity to food. This provides a rationale for studying how positive regulation of hypersensitivity can be dampened in food allergy models.
Allergic airway inflammation and asthma
Allergic airway inflammation and remodeling are driven by Th2 and Th17 cytokines. Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling, directly linking a molecular regulator to positive regulation of hypersensitivity in the lung. IgE also regulates adaptive immune responses, further amplifying airway hypersensitivity.
From positive regulation of hypersensitivity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X causally amplify hypersensitivity? | CRISPR knockout in primary immune or epithelial cells followed by allergen challenge |
| Does a specific point mutation alter signaling gain? | Point-mutation knock-in cell lines with cytokine or mediator readouts |
| Does overexpression of a candidate gene increase hypersensitivity? | Stable overexpression in mast cell or epithelial cell lines |
| Can a tagged protein reveal localization during activation? | Tagged knock-in with imaging and co-immunoprecipitation |
| Which genes are required for IgE-mediated activation? | Genome-wide CRISPR library screening in effector cells |
| Can epigenetic editing reduce food allergy? | Tert methylation editing with IL10 pathway readouts |
How to Study the positive regulation of hypersensitivity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nasal allergen challenge | Clinical and mediator response to allergen | Standardized human hypersensitivity testing |
| RNA sequencing | Transcriptional changes during activation | Identify positive regulators of hypersensitivity |
| Methylation analysis | DNA methylation at regulatory loci | Study Tert methylation in food allergy |
| NADPH oxidase and mitochondrial assays | Oxidative stress and mitochondrial function | Mechanistic studies in allergic rhinitis |
| Cytokine ELISA | IL-4, IL-5, IL-13, IL-17A, IL-10 levels | Quantify amplification of allergic inflammation |
| Flow cytometry | Immune cell activation and IgE receptor expression | Assess effector cell responses |
| CRISPR library screening | Gene requirements for hypersensitivity | Discover novel amplifiers or brakes |
| Imaging of tagged proteins | Subcellular localization during activation | Validate knock-in models |
Allergen challenge and clinical readouts
Standardized nasal allergen challenge is a controlled method to provoke and measure hypersensitivity responses in sensitized individuals, providing a human readout of positive regulation. Symptom scores, mediator measurements, and imaging can be combined to quantify the response.
Transcriptomic and epigenetic profiling
RNA sequencing and methylation analysis can identify genes and pathways that are upregulated during hypersensitivity. Regulation of Tert methylation and its effect on the Tert-IL10 pathway in food allergy illustrates how epigenetic profiling can reveal modulators of hypersensitivity.
Inflammatory and mitochondrial assays
NADPH oxidase activity, mitochondrial function, and inflammatory cytokine production are measurable endpoints in allergic rhinitis models, as shown for LRRC8A. These assays help determine whether a gene positively regulates hypersensitivity through oxidative or metabolic mechanisms.
Cytokine and signaling pathway analysis
IL-17A, IL-4, IL-13, and IgE pathway components can be measured by ELISA, flow cytometry, or reporter assays. Epithelial SIRT6 regulation of IL-17A pathogenicity demonstrates how pathway analysis can link a regulator to allergic airway inflammation. JAK1 and IL-4Ralpha inhibitors such as abrocitinib provide pharmacological validation of these pathways.
How CRISPR Can Be Used to Study GO:0002885 positive regulation of hypersensitivity
Knockout
CRISPR knockout of candidate genes such as LRRC8A or SIRT6 in epithelial or immune cells can test whether the gene is required for positive regulation of hypersensitivity. Loss of LRRC8A reduces NADPH oxidase-mediated inflammation in allergic rhinitis models, supporting a causal role. Knockout of SIRT6 alters IL-17A pathogenicity and airway remodeling, demonstrating the utility of this approach.
Point Mutation
Point-mutation knock-in can model disease-associated variants or phospho-null/phospho-mimetic residues in genes that regulate hypersensitivity. This approach is useful when a single amino acid change is suspected to alter signaling gain in pathways such as IL-17A or IgE receptor signaling.
Knock-in
Knock-in of reporters or tags allows real-time tracking of proteins during allergen challenge. Tagged knock-in of epithelial SIRT6 or cytokine loci can reveal where and when positive regulation occurs in allergic airway inflammation. Knock-in of human IgE receptor components can humanize mouse models for hypersensitivity research.
Overexpression
Overexpression of candidate genes such as LRRC8A or TERT-related constructs can test whether increased dosage amplifies hypersensitivity. Overexpression studies complement knockout by showing sufficiency rather than requirement. In food allergy, modulating Tert-IL10 signaling through overexpression or epigenetic editing can shift the balance toward tolerance.
How EDITGENE Supports positive regulation of hypersensitivity Research
Researchers studying positive regulation of hypersensitivity-related genes often need to determine whether a candidate gene is causally involved in amplifying allergic inflammation or is merely a bystander. This requires precise, reproducible cell models in which the gene of interest can be deleted, mutated, tagged, or overexpressed, followed by functional readouts such as cytokine release, mediator production, or allergen-induced activation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of hypersensitivity research.
Frequently Asked Questions About positive regulation of hypersensitivity
What is GO:0002885 positive regulation of hypersensitivity?
GO:0002885 is a Gene Ontology biological_process term meaning any process that activates or increases the frequency, rate, or extent of hypersensitivity, the exaggerated immune response to antigens.
What genes are involved in positive regulation of hypersensitivity?
Genes include IGHE, FCER1A, IL4, IL5, IL13, IL17A, SIRT6, LRRC8A, TERT, IL10, JAK1, IL4R, KLKB1, TSLP, IL33, IL25, and MS4A2, based on published studies.
How is positive regulation of hypersensitivity measured?
It can be measured by standardized allergen challenge with symptom scores and mediator release, as well as by cytokine assays and transcriptomic profiling in cell and animal models.
What diseases involve positive regulation of hypersensitivity?
Allergic rhinitis, chronic spontaneous urticaria, food allergy, and allergic airway inflammation are prominent examples.
What is the role of IgE in positive regulation of hypersensitivity?
IgE binds to high-affinity receptors on mast cells and basophils and, upon allergen cross-linking, triggers mediator release; IgE also regulates adaptive immune responses, amplifying hypersensitivity.
How does SIRT6 regulate allergic airway inflammation?
Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling, acting as a positive regulator of hypersensitivity in the lung.
Can CRISPR be used to study positive regulation of hypersensitivity?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in hypersensitivity pathways.
What drugs target pathways in positive regulation of hypersensitivity?
Abrocitinib targets JAK1, sebetralstat targets plasma kallikrein, and other therapies target IgE or IL-4Ralpha to reduce hypersensitivity amplification.
What is the difference between hypersensitivity and positive regulation of hypersensitivity?
Hypersensitivity is the exaggerated immune response itself, while positive regulation of hypersensitivity refers to processes that increase its frequency, rate, or extent.
Which experimental models are best for studying positive regulation of hypersensitivity?
Human cell lines with CRISPR edits, primary immune cells, and allergen-challenged animal models are commonly used, with readouts such as cytokine release and mediator production.
Conclusion
GO:0002885 positive regulation of hypersensitivity provides a precise ontological framework for studying how allergic reactions are amplified. The verified literature highlights IgE, epithelial alarmins, Th2/Th17 cytokines, SIRT6, LRRC8A, and Tert-IL10 signaling as key contributors to this process. Targeting these positive regulatory nodes has already produced approved therapies such as abrocitinib and sebetralstat, and continues to drive drug discovery. CRISPR-based cell models are indispensable for determining which genes are causally involved, and they enable the functional validation needed to translate genomic findings into new treatments for allergic disease.
References
- 1. Augé J et al.. 2018. EAACI Position paper on the standardization of nasal allergen challenges.. Allergy 73(8):1597-1608 PMID: 29377177
- 2. Meng L et al.. 2024. LRRC8A drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis.. J Transl Med 22(1):1034 PMID: 39550567
- 3. Maurer M et al.. 2011. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.. Allergy 66(3):317-30 PMID: 21083565
- 4. Blair HA. 2025. Sebetralstat: First Approval.. Drugs 85(11):1499-1505 PMID: 41014446
- 5. Deeks ED et al.. 2021. Abrocitinib: First Approval.. Drugs 81(18):2149-2157 PMID: 34807428
- 6. Quan J et al.. 2023. Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling.. Nat Commun 14(1):8525 PMID: 38135684
- 7. Engeroff P et al.. 2025. IgE in the Regulation of Adaptive Immune Responses.. Immunol Rev 331(1):e70030 PMID: 40322927
- 8. Zeng H et al.. 2024. Regulation of Tert methylation alleviates food allergy via regulating the Tert-IL10 signal pathway.. Immunol Res 72(5):1018-1029 PMID: 39034374
